Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus - Wikidata - wikimedia - TriplyDB

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

http://www.wikidata.org/entity/Q27473236

about

Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759 Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796 Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities Discovery of N -[4-[6- tert -Butyl-5-methoxy-8-(6-methoxy-2-oxo-1 H -pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.Nanolitre-scale crystallization using acoustic liquid-transfer technology.Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase.Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase Resistance mechanisms in HCV: from evolution to intervention.Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.

P2860

Q24303838-2E34A2E3-7E7F-4D20-AC2D-75B45909A71A Q24645702-4438BC55-9F00-472B-A9B0-AEE1A9383C72 Q26783056-F3B386CA-CFB5-4996-9917-A48D71218485 Q27480267-B2585C1E-381E-4F1A-B2B7-B58D03F83EAB Q27480361-27085A0B-8FAD-4524-8DAD-F3B549C52DAD Q27480926-C1DA875A-C15B-4BF5-BF52-DDA34E73BA4C Q27485288-8A29047B-6E05-4876-8802-5830DE64A12A Q27485335-994DEFA4-0BAB-4FFE-B76B-526D4ABD1135 Q27485895-B8AF6321-3C0A-4130-B2DB-DD34B70BAFB4 Q27486249-68FB71D8-5C3F-4407-90F8-F9C5DB50AE2C Q27486813-E0978B56-27FA-4F83-AA99-81C184D2C58E Q27486821-5703F79D-434A-42E2-A4EA-B29E9FAF61D1 Q27487022-1C200EBF-61CC-4FCE-A34E-F822FFC780AF Q27487389-5EA56AD4-EE48-4CFC-8052-ADE6637E85E7 Q27488386-3C21C986-A68F-44BD-856B-7115D1C89784 Q27488428-D8AD1948-D2B1-4835-BEB5-3717A289A3B7 Q27488887-4F449623-A6FB-426D-9089-BF9BC7E58AD1 Q27488958-55104391-74CF-4E3E-AB57-1C65ADF7419C Q27490426-E380E7BA-51D8-4B81-B739-D1BF7C0364CD Q27680539-5E14E2D1-FA53-46C4-B21A-BBA54B926FD6 Q28553112-83CA7023-B548-4F12-9A6C-6EA128BFBBDC Q30375558-2ADA039F-C8E2-40CB-B9F2-B0E5FB959025 Q30464856-A7E31FF0-2BDA-4458-843F-4BB296A8E0D6 Q32183060-FE8097B4-642B-4DC7-83DD-E8323C73096F Q34409020-E173BD74-A92F-41EE-BDF9-AD30E7013D80 Q34489239-A9A5A773-DC39-4F33-90EC-F78EEA8513AE Q34530512-EC75C16E-849A-4608-BCC1-6D7C462B8FF6 Q34597666-1BA49132-BDF7-46AD-B134-B4C29204B225 Q34957256-4171E16F-F1C9-4174-8C0D-38F07659A7CB Q35004972-7ABE6293-5695-4E8F-9887-BCAF2F7DE895 Q35008754-2B2B16E4-9B98-41E7-A37A-781B4E76C783 Q35103718-9A91D57B-7F81-463A-891B-0C9CC72C84E3 Q35260330-91BADCE2-7D9D-411C-9B8E-F7D387865F21 Q35531173-62347850-058E-4A27-B8C9-90FDD39C4C52 Q36276803-90EEC546-6C9C-4385-844A-336ECD80DB0F Q36558549-C4DD5035-84C7-4693-B3EC-86A24FA85136 Q37228736-83309CF9-48D1-44A4-985C-CFF41D7720C2 Q37313166-936B84E4-634E-44BB-9484-22E619232FA2 Q37481292-8E364C77-C24C-406F-A352-16589A2D356A Q37766106-96CEFBBF-974E-4B13-A96C-2DDFF8052439

P2860

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

http://www.wikidata.org/entity/Q27473236

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Selection and Characterization ...... itors of the Hepatitis C Virus

@ast

Selection and Characterization ...... itors of the Hepatitis C Virus

@en

Selection and Characterization ...... itors of the Hepatitis C Virus

@nl

type

label

Selection and Characterization ...... itors of the Hepatitis C Virus

@ast

Selection and Characterization ...... itors of the Hepatitis C Virus

@en

Selection and Characterization ...... itors of the Hepatitis C Virus

@nl

prefLabel

Selection and Characterization ...... itors of the Hepatitis C Virus

@ast

Selection and Characterization ...... itors of the Hepatitis C Virus

@en

Selection and Characterization ...... itors of the Hepatitis C Virus

@nl

P1433

Q27473236-742B2455-A973-4E2C-B188-EBCC1E977290

P1476

Q27473236-B7D203FC-DB07-4A1D-8E5B-852BED8690C0

P2093

Q27473236-06F3400F-88FA-4E2D-8997-B476F5DCC900

Q27473236-0C3E53EA-EC38-46CF-817F-14536CC53E30

Q27473236-0EF2750F-570F-4681-B03C-3D5F53902164

Q27473236-28D76323-D172-4E0F-A6C6-0446878AB876

Q27473236-298D3E85-41EF-4C64-AAE4-D18D30E31037

Q27473236-2FEF5B9B-072D-40BA-8180-F4D010869AE5

Q27473236-47E4CADC-A8D9-4117-9AB1-BD226E9B24A7

Q27473236-4962231D-4DF3-4DAC-B4FF-3DEA0E62F205

Q27473236-57F6D282-9408-470E-AEDC-92EAD8EF446F

Q27473236-5934A5FC-B4AE-4507-9954-D9D0D2DBB029

P2860

Q27473236-07210C6D-E143-41DD-8138-F62DB259EF56

Q27473236-0CC5A9F1-E67C-4A6C-905B-4E94F6323EA0

Q27473236-0EED985A-27DA-4605-89FF-F02984400BDA

Q27473236-167F6F5C-36C7-4B53-86A9-5E36559B88E4

Q27473236-17E4EE21-F085-465D-A590-A395528207B8

Q27473236-299848C9-7103-4F2A-ABA1-D67120CAE898

Q27473236-2C76E50E-088C-410F-98CD-F4E8A0B03D9B

Q27473236-2CF2D599-F9EA-4C8A-97E4-ED3A78233237

Q27473236-2E447D81-AA50-4147-B01B-A36C774F5C8B

Q27473236-31B09971-3912-45E8-8B4D-213923018B2F

P304

Q27473236-2A3267BD-ED3F-463D-9B02-9339CB72ED2A

P31

Q27473236-52B2909A-15BA-47A5-BA51-D2ADF884EEFD

P356

Q27473236-606D1675-5C5A-49AA-8BFE-E9ED7F448B56

P433

Q27473236-4079EF56-07E4-4ED6-9E25-AEDB336DBA67

P478

Q27473236-B1A12367-D98D-4FA9-BD10-4311F65A0370

P577

Q27473236-F898C146-488D-4DA1-BB1F-CC9247DC07BC

P698

Q27473236-04985BF5-1F5A-4C1D-8D10-C8A5DC5E6193

P921

Q27473236-6C980045-D31A-4E93-A6B4-0E0D36C35F40

P932

Q27473236-5CF407C1-BCD4-43C9-AFBA-FE3371CA18D6

P356

P1433

Journal of Virology

P1476

Selection and Characterization ...... itors of the Hepatitis C Virus

@en

P2093

Anthony M Giannetti

http://www.w3.org/2001/XMLSchema#string

Connie Oshiro

http://www.w3.org/2001/XMLSchema#string

Gisele Tavares

http://www.w3.org/2001/XMLSchema#string

Hyunsoon Kang

http://www.w3.org/2001/XMLSchema#string

Isabel Nájera

http://www.w3.org/2001/XMLSchema#string

Julian Symons

http://www.w3.org/2001/XMLSchema#string

Klaus Klumpp

http://www.w3.org/2001/XMLSchema#string

Michelle F Browner

http://www.w3.org/2001/XMLSchema#string

Nick Cammack

http://www.w3.org/2001/XMLSchema#string

Samir Ali

http://www.w3.org/2001/XMLSchema#string

P2860

Wide range of quasispecies diversity during primary hepatitis C virus infection

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

Crystal structures of active and inactive conformations of a caliciviral RNA-dependent RNA polymerase

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition

P304

6146-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02628-05

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16731953

http://www.w3.org/2001/XMLSchema#string

P921

P932

1472602

http://www.w3.org/2001/XMLSchema#string